Cargando…
JIB-04, A Small Molecule Histone Demethylase Inhibitor, Selectively Targets Colorectal Cancer Stem Cells by Inhibiting the Wnt/β-Catenin Signaling Pathway
Although several epigenetic modulating drugs are suggested to target cancer stem cells (CSCs), additional identification of anti-CSC drugs is still necessary. Here we showed that JIB-04, a pan-selective inhibitor of histone demethylase(s), was identified as a small molecule that selectively target c...
Autores principales: | Kim, Min Seong, Cho, Hye In, Yoon, Hee Jung, Ahn, Ye-Hyeon, Park, Eun Jung, Jin, Yan Hua, Jang, Yeun Kyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919936/ https://www.ncbi.nlm.nih.gov/pubmed/29700375 http://dx.doi.org/10.1038/s41598-018-24903-0 |
Ejemplares similares
-
JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells
por: Lee, Jina, et al.
Publicado: (2022) -
JIB-04, a histone demethylase Jumonji C domain inhibitor, regulates phenotypic switching of vascular smooth muscle cells
por: He, Yi, et al.
Publicado: (2022) -
The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth
por: Parrish, Janet K., et al.
Publicado: (2018) -
JIB 2003: fidèlesàelles-mêmes
por: J.-M.M.
Publicado: (2003) -
JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis
por: Son, Juhee, et al.
Publicado: (2021)